Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer von EDER, Joseph Paul, VANDE WOUDE, George F, BOERNER, Scott A, LO RUSSO, Patricia M

Volltext

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 von EDER, Joseph Paul, SHAPIRO, Geoffrey I, MCCALLUM, Stewart, HEATH, Elisabeth I, BOERNER, Scott A, LORUSSO, Patricia M, APPLEMAN, Leonard J, ZHU, Andrew X, MILES, Dale, KEER, Harold, CANCILLA, Belinda, CHU, Felix, HITCHCOCK-BRYAN, Suzanne, SHERMAN, Laurie

Volltext

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer von Boerner, Julie L, Nechiporchik, Nicole, Mueller, Kelly L, Polin, Lisa, Heilbrun, Lance, Boerner, Scott A, Zoratti, Gina L, Stark, Karri, LoRusso, Patricia M, Burger, Angelika

Volltext

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma von Goncalves, Priscila H, Heilbrun, Lance K, Barrett, Michael T, Kummar, Shivaani, Hansen, Aaron R, Siu, Lillian L, Piekarz, Richard L, Sukari, Ammar W, Chao, Joseph, Pilat, Mary Jo, Smith, Daryn W, Casetta, Lindsay, Boerner, Scott A, Chen, Alice, Lenkiewicz, Elizabeth, Malasi, Smriti, LoRusso, Patricia M

Volltext

PAK1 Phosphorylation of MEK1 Regulates Fibronectin-Stimulated MAPK Activation von Slack-Davis, Jill K., Eblen, Scott T., Zecevic, Maja, Boerner, Scott A., Tarcsafalvi, Adel, Diaz, H. Bruce, Marshall, Mark S., Weber, Michael J., Parsons, J. Thomas, Catling, Andrew D.

Volltext

Integrin Connections Map: To Infinity and beyond von Martin, Karen H., Slack, Jill K., Boerner, Scott A., Martin, Clifford C., Parsons, J. Thomas

Volltext

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with A... von LoRusso, Patricia M, Li, Jing, Burger, Angelika, Heilbrun, Lance K, Sausville, Edward A, Boerner, Scott A, Smith, Daryn, Pilat, Mary Jo, Zhang, Jie, Tolaney, Sara M, Cleary, James M, Chen, Alice P, Rubinstein, Lawrence, Boerner, Julie L, Bowditch, Adam, Cai, Dongpo, Bell, Tracy, Wolanski, Andrew, Marrero, Allison M, Zhang, Yiping, Ji, Jiuping, Ferry-Galow, Katherine, Kinders, Robert J, Parchment, Ralph E, Shapiro, Geoffrey I

Volltext

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics von LoRusso, Patricia M, Boerner, Scott A, Seymour, Lesley

Volltext

Clinical experience of MEK inhibitors in cancer therapy von Wang, Ding, Boerner, Scott A., Winkler, James D., LoRusso, Patricia M.

Volltext

Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? von Lorusso, Patricia M, Boerner, Scott A, Hunsberger, Sally

Volltext

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop von LORUSSO, Patricia M, CANETTA, Renzo, WAGNER, John A, BALOGH, Erin P, NASS, Sharyl J, BOERNER, Scott A, HOHNEKER, John

Volltext

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial von LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Liang, Winnie S., Carpten, John, Craig, David W., Solit, David B., Bryce, Alan H., Kiefer, Jeffrey A., Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A., Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane, Hendricks, William P. D., Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N., Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D., Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S., Petricoin, Emanuel F., Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J., Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W., Cowey, C. Lance, Trent, Jeffrey M.

Volltext

Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials von Gupta, Sachin, Hunsberger, Sally, Boerner, Scott A, Rubinstein, Larry, Royds, Robert, Ivy, Percy, LoRusso, Patricia

Volltext

Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells von Kottke, Timothy J., Blajeski, April L., Meng, X. Wei, Svingen, Phyllis A., Ruchaud, Sandrine, Mesner, Peter W., Boerner, Scott A., Samejima, Kumiko, Henriquez, Nicholas V., Chilcote, Tamie J., Lord, Janet, Salmon, Michael, Earnshaw, William C., Kaufmann, Scott H.

Volltext

Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? von LoRusso, Patricia M, Anderson, Aparna B, Boerner, Scott A, Averbuch, Steven D

Volltext

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170) von Maldonado, Edward, Rathmell, W Kimryn, Shapiro, Geoffrey I, Takebe, Naoko, Rodon, Jordi, Mahalingam, Devalingam, Trikalinos, Nikolaos A, Kaleblasty, Arash R, Parikh, Mamta, Boerner, Scott A, Balido, Celene, Krings, Gregor, Burns, Timothy F, Bergsland, Emily K, Munster, Pamela N, Ashworth, Alan, LoRusso, Patricia, Aggarwal, Rahul R

Volltext

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors von Cecchini, Michael, Walther, Zenta, Wei, Wei, Hafez, Navid, Pilat, Mary Jo, Boerner, Scott A, Durecki, Diane E, Eder, Joseph P, Schalper, Kurt A, Chen, Alice P, LoRusso, Patricia

Volltext

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team von LoRusso, Patricia M, Boerner, Scott A, Pilat, Mary Jo, Forman, Karen M, Zuccaro, Clarice Y, Kiefer, Jeffrey A, Liang, Winnie S, Hunsberger, Sally, Redman, Bruce G, Markovic, Svetomir N, Sekulic, Aleksandar, Bryce, Alan H, Joseph, Richard W, Cowey, C Lance, Fecher, Leslie Anne, Sosman, Jeffrey Alan, Chapman, Paul B, Schwartz, Gary K, Craig, David W, Carpten, John D, Trent, Jeffrey M

Volltext

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors von Burris, Howard A., Jones, Suzanne F., Williams, Daphne D., Kathman, Steven J., Hodge, Jeffrey P., Pandite, Lini, Ho, Peter T. C., Boerner, Scott A., LoRusso, Patricia

Volltext

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer von CHIANESE-BULLOCK, Kimberly A, IRVIN, William P, YUAN, Arlene, HOGAN, Kevin T, SLINGLUFF, Craig L, PETRONI, Gina R, MURPHY, Cheryl, SMOLKIN, Mark, OLSON, Walter C, COLEMAN, Elizabeth, BOERNER, Scott A, NAIL, Carmel J, NEESE, Patrice Y

Volltext